IO Biomarkers: Q&A Session
Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions

Released: August 10, 2020

Expiration: August 09, 2021

Jamie E. Chaft
Jamie E. Chaft, MD
John L. Marshall
John L. Marshall, MD
Scot Niglio
Scot Niglio, MD

Activity

Progress
1
Course Completed

In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as:

  • Selecting immuno-oncology vs targeted therapy in MSI-high cancers with co-occurring alterations (eg, BRCA, HER2, BRAF, NTRK)
  • Switching to a new immuno-oncology strategy at progression on first-line immune checkpoint inhibition
  • Neoadjuvant treatment with immune checkpoint inhibitors
  • Financial considerations when selecting chemotherapy vs immuno-oncology

Content based on an online CME program supported by an educational grant from Merck Sharp & Dohme Corp.

Link to full program: https://www.clinicaloptions.com/oncology/programs/biomarkers2020